Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced that preclinical studies of Probudur™, a proprietary patented injectable, long-acting “local anesthetic” Liposomal (Hydro) Gel Technology for postoperative pain management, have been initiated under an agreement with Charles River Laboratories
March 22, 2021
· 5 min read